Lawrence D. Ginsberg, MD

Lawrence D. Ginsberg, M.D., is a seasoned psychiatrist with over four decades of experience in the field. He is the founder and CEO of Red Oak Psychiatry Associates, P.A., established in 1991. Dr. Ginsberg specializes in treating a wide range of psychiatric conditions, including mood disorders, anxiety disorders, schizophrenia, autism, PTSD, and ADHD, providing care to patients starting from three years of age. Throughout his career, Dr. Ginsberg has been deeply involved in psychiatric clinical research, serving as a principal investigator in over 200 clinical trials. His expertise in psychopharmacology has led him to lecture frequently for various pharmaceutical companies on related topics. He has also contributed extensively to the academic community with over 100 publications, including journal articles, abstracts, and monographs. In addition to his clinical and research endeavors, Dr. Ginsberg is an active member of the editorial board of two medical journals. His commitment to advancing the field of psychiatry is evident through his extensive work in both patient care and academic contributions, reflecting a lifelong dedication to improving mental health outcomes.

• B.S. in Chemistry, magna cum laude - University of Miami

• Diplomat American Board of Addiction Medicine

• Life Fellow American Society for Adolescent Psychiatry
• Fellow American Society of Addiction Medicine
• Fellow American Society of Clinical Psychopharmacology

• American Medical Association
• American Psychiatric Association
• American Academy of Psychiatry and the Law
• American Society of Addiction Medicine
• American Association for Physician Leadership
• American Society for Adolescent Psychiatry
• American College of Legal Medicine
• American Society of Clinical Psychopharmacology
• International Society for Autism Research
• Texas Society of Psychiatric Physicians
• Texas Medical Association
• Harris County Medical Society
• Houston Psychiatric Society

• United States Holocaust Museum
• Houston Holocaust Museum

Eaglestein, W.H., Ginsberg, L.D., and Mertz, P.M., The Effect of Steroidal and Nonsteroidal Anti-Inflammatory Agents on Ultraviolet-Induced Inflammation, Archives of Dermatology 1979; 115: 1421-1423.

Ginsberg, L.D., Decisions without Data, Chapter in Psychiatry: A Problem-Oriented Approach, Moffic, S., Silverman, S., and Adams, G., Medical Exam Publishing Company, January, 1986.

Ginsberg, L.D., The Insanity Defense and Alternatives, The Houston Lawyer 1986; 23 (5).

Defrance JF, Ginsberg LD, Rosenberg BA, Sharma JC, Topographical Analysis of Adolescent Affective Disorders, Int J Neurosci. 1996; 86: 119-141.

Defrance JF, Smith S, Schweitzer FC, Ginsberg L, Sands S., Topographical Analyses of Attention Disorders of Childhood, Int J Neurosci. 1996; 87: 41-61.

Defrance JF, Hymel C, Trachtenberg MC, Ginsberg LD, Schweitzer FC, Estes S, Chen TJ, Braverman ER, Cull CJ, Blum K, Enhancement of Attention Processing by Kantroll in Healthy Humans: a Pilot Study, Clin Electroencephalogr. 1997; 28: 68-75.

Defrance JF, Sands S, Schweitzer FC, Ginsberg L, Sharma JC, Age-related Changes in Cognitive ERP’s of Attenuation, Brain Topogr. 1997; 9: 283-293.

Mullen J., Reinstein M., Bari M., Ginsberg L.D., Sandler N.: Quetiapine and Risperidone in Outpatients with Psychotic Disorders: Results of the QUEST Trial conference abstract. Schizophrenia Research 1999; 1, 2 & 3: 290.

Mullen J., Reinstein M., Bari M., Ginsberg L., and Sandler N.: Quetiapine and Risperidone in Outpatients with Psychotic Disorders: Results of the QUEST Trial. Poster presented at the International Congress on Schizophrenia Research Biennial meeting April 17-21, 1999; Santa Fe, NM.

Reinstein M., Bari M., Ginsberg L., Sandler N., and Mullen J.: Quetiapine and Risperidone in Outpatients with Psychotic Disorders: Results of the QUEST Trial. Poster presented at the 152^nd annual meeting of the American Psychiatric Association, May 15-20, 1999; Washington, D.C.

Mullen J., Reinstein M., Bari M., Ginsberg L., and Sandler N.: Quetiapine and Risperidone in Outpatients with Psychotic Disorders: Results of the QUEST Trial. Poster presented at the 39^th Annual Meeting of the New Clinical Drug Evaluation Unit, June 1-4, 1999; Boca Raton, FL.

Mullen J., Bari M., Reinstein M., Sandler N., Ginsberg L.D.: Quetiapine and Risperidone in Outpatients with Psychoses. Poster presented at the 11^th World Congress on Psychiatry, August 6-11, 1999; Hamburg, Germany.

Mullen J., Reinstein M., Bari M., Ginsberg L., and Sandler N.: Quetiapine and Risperidone in Outpatients with Psychotic Disorders: Results of the QUEST Trial. Journal of the European College of Neuropsychopharmacology 1999; 9 (5): S269.

DeVeaugh-Geiss J., Conners C.K., Sarkis E.H., Winner P.K., Ginsberg L.D., Hemphill J.M., Laurenza A.,

Asgharnejad M., Barrows C.F., Webster C.J.: Open Label Efficacy of 1555U88 for the Treatment of ADHD in Children. Poster presented at the 40^th annual meeting of New Clinical Drug Evaluation Unit; May 30-June 2, 2000, Boca Raton, FL.

DeVeaugh-Geiss J., Conners C.K., Sarkis E.H., Winner P.K., Ginsberg L.D., Hemphill J.M., Laurenza A.,

Asgharnejad M., Webster C.J. Barrows C.F.: Efficacy of 1555U88 in Children with Attention-Deficit/Hyperactivity Disorder. European Neuropsychopharmacology 2000; 10 (S3): 393

Bowden, C.L., Ascher, J.A., Calabrese, J.R., Ginsberg, L.D., Greene, P., Montgomery, P., Reimherr, F.W. Lamotrigine: Evidence for Mood Stabilization in Bipolar I Depression. Poster presented at the 154^th annual meeting of the American Psychiatric Association, May 5-10, 2001; New Orleans, LA.

Ginsberg, L., Adler, L., Casat, C., et al. Lamotrigine: Evidence for Mood Stabilization in Bipolar I Depression. Poster presented at the 41^st annual meeting of the New Clinical Drug Evaluation Unit; May 23-28, 2001; Phoenix, Ariz.

DeVeaugh-Geiss J., Conners C.K., Sarkis E.H., Winner P.K., Ginsberg L.D., Hemphill J.M., Laurenza A.,

Asgharnejad M., Barrows C.F., Webster C.J.: Efficacy of GW320659 in Children with Attention-Deficit/Hyperactivity Disorder, Journal of the American Academy of Child & Adolescent Psychiatry 2002; 41:914-20.

Ginsberg, L. Topiramate Use in Refractory Bipolar Disorder. Poster presented at 54^th American Psychiatric Association Institute on Psychiatric Services; October 9-13, 2002; Chicago, Ill.

Ginsberg, L. CME Monograph, Case No. 6: Bipolar Depression in the Older Adult. American Academy for Healthcare Education, Jan. 15, 2003.

Ginsberg, L. CME Monograph: Pharmacologic Interventions for the Treatment of Bipolar Disorder. CNS News, March 2003.

Ginsberg, L., Sachs, G., Ketter, T., et al. Effects of Mood Stabilizers on Body Weight in Bipolar I Disorder. Poster presented at the 156^th annual meeting of the American Psychiatric Association, May 17-22, 2003; San Francisco, CA.

Ginsberg, L., Sachs, G., Ketter, T., et al. Effects of Lamotrigine and Lithium on Body Weight in Bipolar I Disorder. Poster presented at the 43^rd annual meeting of the New Clinical Drug Evaluation Unit, May 27-30, 2003; Boca Raton, FL.

Yatham, L.D., Khan, A., Ginsberg, L., et al. Effects of Lamotrigine on Neurocognitive Measures in Bipolar I Patients. Poster presented at the 5^th International Conference on Bipolar Disorders, June 12-14, 2003; Pittsburgh, PA.

Sachs, G., Young, A.H., Ginsberg, L., et al. Effects of Lithium and Lamotrigine Prophylaxis Therapy on Body Weight in Patients with Bipolar I Disorder. Poster presented at the 5^th International Conference on Bipolar Disorders, June 12-14, 2003; Pittsburgh, PA.

Yatham, L., Davis, K., Khan, A., Ginsberg, L., Asnis, G., Goodwin, F., Effects of Lamotrigine on Neurocognitive Measures in Bipolar I Patients. European Neuropsychopharmacology 2003, 13 (S4): 227-228.

Ginsberg, L., Calabrese, J, Bowden, C., et al. Effects of Mood Stabilizers on Body Weight in Bipolar I Disorder. Poster presented at the 55^th American Psychiatric Association Institute on Psychiatric Services; October 29-November 2, 2003; Boston, MA.

Bowden, C., Asnis, G., Ginsberg, L., et al.: Safety and Tolerability of Lamotrigine for Bipolar Disorder, Drug Safety 2004; 27: 173-184.

Blumenfield, M., Bowden, C., Gazda, T., Ginsberg, L., Gupta, S., Ketter, T., Skiba, W., Weisler, R. CME Monograph: New Perspectives in the Treatment of Bipolar Disorder: A Roundtable Discussion. CNS News, April 2004.

Ginsberg, L. Safety and Efficacy of Extended-Release Carbamazepine for Pediatric Bipolar Disorder Patients. Poster presented at the 157^th annual meeting of the American Psychiatric Association, May 1-6, 2004; New York, N.Y.

Ginsberg, L. Safety and Efficacy of Extended-Release Carbamazepine for Adult Bipolar Disorder Patients. Poster presented at the 157^th annual meeting of the American Psychiatric Association, May 1-6, 2004; New York, N.Y.

Sachs, G., Meredith, C., Ginsberg, L., et al.: The Long-Term Impact of Mood Stabilizers on Body Weight. Poster presented at the 157^th annual meeting of the American Psychiatric Association, May 1-6, 2004; New York, N.Y.

Ginsberg, L. Extended-Release Carbamazepine for the Treatment of Bipolar Disorder. Poster presented at 44^th annual meeting of the New Clinical Drug Evaluation Unit, June 1-4, 2004; Phoenix, AZ.

Sachs, G., Meredith, C., Ginsberg, L., et al.: The Long-Term Impact of Mood Stabilizers on Body Weight. Poster presented at 44^th annual meeting of the New Clinical Drug Evaluation Unit, June 1-4, 2004; Phoenix, AZ.

Ginsberg, L. Efficacy and Safety of ERC-CBZ in the Treatment of Bipolar II Disorder. Poster presented the 56^th American Psychiatric Association Institute on Psychiatric Services; October 6-10, 2004; Atlanta, GA.

Ginsberg, L. Extended-Release Carbamazepine Capsules in Bipolar Disorder. Poster presented at the 17^th annual US Psychiatric and Mental Health Congress; November 18-21, 2004; San Diego, CA.

Ginsberg, L. Safety and Efficacy of Extended-Release Carbamazepine Capsules in Patients with Bipolar Disorder: QD vs. BID dosing. Poster presented at the 17^th annual US Psychiatric and Mental Health Congress; November 18-21, 2004; San Diego, CA.

Sachs, G., Meredith, C., Ginsberg, L., et al.: The Long-Term Impact of Mood Stabilizers on Body Weight. . Poster presented at the 17^th annual US Psychiatric and Mental Health Congress; November 18-21, 2004; San Diego, CA.

Khan, A., Ginsberg, L., Asnis, G., et al: Effect of Lamotrigine on Cognitive Complaints in Patients with Bipolar I Disorder, J Clin Psychiatry 2004; 65: 1483-1490.

Ginsberg, L. The Effectiveness of Changing to Carbamazepine Extended-Release Capsules in Bipolar Disorder. Poster presented at the 158^th annual meeting of the American Psychiatric Association, May 21-26, 2005; Atlanta, GA.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients. Poster presented at the 158^th annual meeting of the American Psychiatric Association, May 21-26, 2005; Atlanta, GA.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Pediatric and Adolescent Bipolar Disorder Patients. Poster presented at the 158^th annual meeting of the American Psychiatric Association, May 21-26, 2005; Atlanta, GA.

Ginsberg, L. Safety of Extended-Release Carbamazepine in Bipolar Disorder: Implications of Polypharmacy. Poster presented at the 6^th International Conference on Bipolar Disorder, June 16-18, 2005; Pittsburgh, PA.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients. Poster presented at the 6^th International Conference on Bipolar Disorder, June 16-18, 2005; Pittsburgh, PA.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients. Poster presented the 57^th American Psychiatric Association Institute on Psychiatric Services; Oct. 5-9, 2005; San Diego, CA.

Swann, A., Cutler, A., Ginsberg, L., Ketter, T., and Weisler, R. CME Monograph: Do No Harm: Safe Use of Pharmacologic Agents for Bipolar Disorder. CNS News, October 2005.

Ginsberg, L., Segars, L. Safety of extended-release carbamazepine in bipolar disorder: implications of polypharmacy. Poster presented at the annual American College of Clinical Pharmacy; October 23-26, 2005; San Francisco, CA.

Ginsberg, L., Segars, L. The effectiveness of changing to carbamazepine extended-release capsules in bipolar disorder. Poster presented at the annual American College of Clinical Pharmacy; October 23-26, 2005; San Francisco, CA.

Goodman, D., Weiss, M., Ginsberg, L., Hodgkins, P., Mays, D. Naturalistic study of mixed amphetamine salts XR for adult ADHD. Poster presented at the annual American College of Clinical Pharmacy; October 23-26, 2005; San Francisco, CA.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients. Poster presented the 18^th annual US Psychiatric and Mental Health Congress; November 7-10, 2005; Las Vegas, NV.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Pediatric Bipolar Disorder Patients. Poster presented the 18^th annual US Psychiatric and Mental Health Congress; November 7-10, 2005; Las Vegas, NV.

Goodman, D.W., Ginsberg, L., Weisler, R.H., Cutler, A.J., and Hodgkins, P. An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (Q.U.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults with ADHD, CNS Spectrums 2005; 10 (Suppl 20): 26-34.

Ginsberg, L. Efficacy and Safety of Lamotrigine for Adults with Bipolar Disorder in a Private Practice Setting, CNS Spectrums 2006; 11 (5): 376-382.

Ginsberg, L. Carbamazepine Extended-Release Capsules in the Treatment of Bipolar Disorder, Annals of Clinical Psychiatry 2006; 18(S1): 1.

Ginsberg, L. Carbamazepine Extended-Release Capsules: A Retrospective Review Its Use in Children and Adolescents, Annals of Clinical Psychiatry 2006; 18(S1): 3-7.

Ginsberg, L. Carbamazepine Extended-Release Capsules Use in Bipolar Disorder: Efficacy and Safety in Adult Patients, Annals of Clinical Psychiatry 2006; 18(S1): 9-14.

Ginsberg, L. Outcomes and Length of Treatment with Carbamazepine Extended-Release Capsules in Bipolar Disorder, Annals of Clinical Psychiatry 2006; 18(S1): 15-18.

Ginsberg, L. Safety of Carbamazepine Extended-Release Capsules in Bipolar Disorder Polypharmacy, Annals of Clinical Psychiatry 2006; 18(S1): 19-22.

Ginsberg, L. Predictors of Response to Carbamazepine Extended-Release Capsules in the Treatment of Bipolar Disorder, Annals of Clinical Psychiatry 2006; 18(S1): 23-26.

Ginsberg, L. Safety and Efficacy of Carbamazepine Extended-Release Capsules in Patients with Bipolar Disorder: QD v. BID, Annals of Clinical Psychiatry 2006; 18(S1): 27-30.

Ginsberg, L. A Retrospective Analysis of Changing From alternative Agents to Carbamazepine Extended-Release Capsules in Bipolar Disorder, Annals of Clinical Psychiatry 2006; 18(S1): 31-34.

Ginsberg, L. Safety and Efficacy of Lamotrigine (Lamictal®) for Adult Bipolar Disorder Patients Greater Than 55 Years Old. Poster presented at the 159^th annual meeting of the American Psychiatric Association, May 20-25, 2006; Toronto, ON.

Ginsberg, L., Weisler, R., Gazda, T., Kerkering, J. A Randomized, Double-Blind, Parallel-Group Trial of Twice-Daily and Once-Daily Carbamazepine Extended-Release Capsules in Bipolar Disorder: Analysis of Safety and Tolerability. Poster presented at the 46^th annual meeting of the New Clinical Drug Unit, June 12-15, 2006; Boca Raton, FL.

Weisler, R., Ginsberg, L., Gazda, T., Kerkering, J. Comparative Efficacy of Twice-Daily and Once-Daily Carbamazepine Extended-Release Capsules in Bipolar Disorder: Results from a Double-Blind, Parallel-Group Trial. Poster presented at the 46^th annual meeting of the New Clinical Drug Unit, June 12-15, 2006; Boca Raton, FL.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients Greater Than 55 Years Old. Poster presented at the 58^th annual meeting of the American Psychiatric Association Institute on Psychiatric Services; Oct. 5-8, 2006; New York, N.Y.

El-Mallakh, R., Weisler, R., Townsend, M., Ginsberg, L. Bipolar II Disorder: Current and Future Treatment Options, Annals of Clinical Psychiatry 2006; 18(4): 259-266.

Ginsberg, L. Safety and Efficacy of Lamotrigine for Adult Bipolar Disorder Patients Greater Than 55 Years Old. Poster presented at the 19^th US Psychiatric and Mental Health Conference; Nov. 16-19, 2006; New Orleans, LA.

Ginsberg, L., Schreckengost, J., Krishnan, S. Effect of Lisdexamfetamine Dimesylate on Parent-Rated Measures of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6 to 12 Years With ADHD: A Secondary Analysis. Poster presented at the 20^th US Psychiatric and Mental Health Conference; Oct. 11-14, 2007; Orlando, FL.

Ginsberg, L., Schreckengost, J., Krishnan, S. Effect of Lisdexamfetamine Dimesylate on Parent-Rated Measures of Oppositional Behavior in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis. Poster presented at the 20^th US Psychiatric and Mental Health Conference; Oct. 11-14, 2007; Orlando, FL.

Carson, W., Nyilas, M., Forbes, R., Pikalov, A., McQuade, R., Ivanova, S., Owen, R., Ginsberg, L.,Wagner, K. Acute Efficacy of Aripiprazole for the Treatment of Bipolar I Disorder in Pediatric Patients, Schizophrenia Research

Feb 2008; 98( S): 42

Weisler, R., Kalali, A., Cutler, J., Gazda, T., Ginsberg, L. Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder, Psychiatry 2008; 2008; 5 (3): 35-48.

Spencer, T., Greenbaum, M., Ginsberg, L., Murphy, W., Farrand, K.  Open-Label Coadministration of Guanfacine Extended Release and Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Poster presented at the 161^st annual meeting of the American Psychiatric Association, May 3-8, 2008; Washington, DC.

Weisler, R., Kalali, A., Cutler, J., Gazda, T., Ginsberg, L. Safety of Carbamazepine Extended-Release Capsules Used in Combination with Other Psychotropic Medications for the Treatment of Bipolar I Disorder, Psychiatry 2008; 2008; 5 (5): 49-60.

Lopez, F., Ginsberg, L. Effect of Lisdexamfetamine Dimesylate on Parent-Rated Measures in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis, Postgraduate Medicine; 2008; 120 (3): 89-102.

Findling, R., Ginsberg, L., Jain, R., Gao, J., Richards, C. A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder. Poster presented at the American Academy of Child & Adolescent Psychiatry 55^th annual meeting Oct. 28-Nov. 2, 2008; Chicago, IL.

Ginsberg, L., Spencer, T., Greenbaum, M., Murphy, W., Sea D. Open-Label Coadministration of Guanfacine Extended Release and Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Poster presented at the 21^st US Psychiatric and Mental Health Conference; Oct. 30-Nov. 2, 2008; San Diego, CA.

Ginsberg, L., Jain, R., Gao, J., Richards, C., Findling, R. A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder. Poster presented at the 21^st US Psychiatric and Mental Health Conference; Oct. 30-Nov. 2, 2008; San Diego, CA.

Ginsberg, L., Physicians’ Impressions in Once-Daily Treatment of Patients Diagnosed With Attention-Deficit/Hyperactivity Disorder: A Survey on Treatment Efficacy and Duration. Poster presented at the 21^st US Psychiatric and Mental Health Conference; Oct. 30-Nov. 2, 2008; San Diego, CA.

Ginsberg, L., Sprainis, M., Allen, J. A Prospective Case Series of 5 Patients Treated With Vagus Nerve Stimulation For Depression. Poster presented at the 21^st US Psychiatric and Mental Health Conference; Oct. 30-Nov. 2, 2008; San Diego, CA.

Ginsberg, L., Jain, R., Gao, J., Richards, C., Findling, R. A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder. Poster presented at the 20^th CHADD Conference; Nov. 12-15, 2008; Anaheim, CA.

Greenbaum, M., Spencer, T., Murphy, W., Ginsberg, L., Sea, D. Open-Label Coadministration of Guanfacine Extended Release and Stimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Poster presented at the 2009 College of Psychiatric and Neurologic Pharmacists meeting; April 19-22, 2009; Jacksonville, FL.

Ginsberg, L., Arnold, V., Gao, J., Richards, C., Findling, R. Parental evaluation of Lisdexamfetamine Dimesylate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. Poster presented at the 162^nd annual meeting of the American Psychiatric Association, May 16-21, 2009; San Francisco, CA.

Katic, A., Ginsberg, L., Jain, R., Richards, C., Adeyi, B., Babcock, T., Dirks, B., Scheckner, B., Findling, R. Improvement in Emotional Expression in Children with Attention-Deficit/Hyperactivity Disorder Treated with 20 to 70 mg/day Lisdexamfetamine Dimesylate. Poster presented at the 162^nd annual meeting of the American Psychiatric Association, May 16-21, 2009; San Francisco, CA.

Turgay, A., Ginsberg, L., Jain, R., Gao, J., Richards, C., Findling, R. Improvement in Executive Function in Children with Attention-Deficit/Hyperactivity Disorder Treated with 20 to 70 mg/day Lisdexamfetamine Dimesylate. Poster presented at the 162^nd annual meeting of the American Psychiatric Association, May 16-21, 2009; San Francisco, CA.

Turgay, A., Ginsberg, L., Jain, R., Findling, R. A Dose-Optimization Study of the Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder. Poster presented at the 86^th Annual conference of the Canadian Paediatric Society; June 23-27, 2009; Ottawa, Canada.

Findling, R., Ginsberg, L., Jain, R., Gao, J, Richards, C. A Dose-Optimization Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder. Poster presented at the International Conference sponsored by the European Society for Child and Adolescent Psychiatry; August 22-26, 2009; Budapest, Hungary.

Gwin, K., Ginsberg, L., Arnold, V., Gao, J., Richards, C., Findling, R., Bordic, M. Parental evaluation of Lisdexamfetamine Dimesylate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. Poster presented at the 21^st CHADD Conference; Oct. 7-10, 2009; Cleveland, OH.

Turgay, A., Ginsberg, L., Jain, R., Gao, J., Richards, C., Curtiss, S., Findling, R. Improvement in Executive Function in Children with Attention-Deficit/Hyperactivity Disorder Treated with 20 to 70 mg/day Lisdexamfetamine Dimesylate. Poster presented at the 61^st American Psychiatric Association Institute on Psychiatric Services; Oct. 8-11, 2009; New York, NY.

Spencer, T., Greenbaum, M., Ginsberg, L., Murphy, W. Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, Journal of Child and Adolescent Psychopharmacology 2009; 19 (5): 501-510.

Ginsberg, L., Katic, A., Adeyi, B., Dirks, B., Babcock, T., Lasser, R., Scheckner, B. Treatment Outcomes with Lisdexamphetamine Dimesylate for Adults with Attention-Deficit/Hyperactivity Disorder Stratified by Baseline Severity. Poster presented at the 22^nd US Psychiatric and Mental Health Conference; Nov. 2-5, 2009; Las Vegas, NV.

Findling, R., Ginsberg, L., Jain, R., Gao, J. Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization Study, Journal of Child and Adolescent Psychopharmacology 2009; 19 (6): 649-662.

Ginsberg, L.D. Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients with Major Depressive Disorder, CNS Spectrums 2009; 14: 12 (Suppl 12).

Ginsberg, L., Sprainis, M., Oubre, A., Daoud, Y. L-methylfolate-Antidepressant Combination Therapy at Treatment Initiation for a Major Depressive Episode Produces Major Clinical Improvement and Decreases Time to Symptom Reduction. Poster presented at the Virginia Council of Nurse Practitioners 2010 Annual Conference; March 4-7, 2010; Reston, VA.

Ginsberg, L., Jain, R., Murphy, W., Lyne, A., Rubin, J., Youcha, S. Response and Symptomatic Remission With Open-Label Coadministration of Guanfacine Extended Release and Stimulants for ADHD. Poster presented at the 163^rd annual meeting of the American Psychiatric Association, May 22-26, 2010; New Orleans, LA.

Ginsberg, L., Sprainis, M., Oubra, O., Daoud, Y. L-methylfolate-Antidepressant Combination Therapy at Treatment Initiation for a Major Depressive Episode Produces Major Clinical Improvement and Decreases Time to Symptom Reduction. Poster presented at the 163^rd annual meeting of the American Psychiatric Association, May 22-26, 2010; New Orleans, LA.

Ginsberg, L. Long-term safety, tolerability, and efficacy of extended-release carbamazepine in a large clinical practice: a chart review study. Poster presented at the 163^rd annual meeting of the American Psychiatric Association, May 22-26, 2010; New Orleans, LA.  

Ginsberg, L. Long-term Treatment of Bipolar Disorder with Carbamazepine Extended-Release Capsules in Adults, Adolescents, and Children. US Psychiatry, 2010; 3:6-10.

Ginsberg, L., Jain, R., Murphy, W., Lyne, A., Rubin, J., Youcha, S. Response and Symptomatic Remission With Open-Label Coadministration of Guanfacine Extended Release and Stimulants for ADHD. Poster presented at the 62^nd Institute of Psychiatric Services, Oct. 14-17, 2010; Boston, MA.

Ginsberg, L., Sprainis, M., Oubra, O., Daoud, Y. L-methylfolate-Antidepressant Combination Therapy at Treatment Initiation for a Major Depressive Episode Produces Major Clinical Improvement and Decreases Time to Symptom Reduction. Poster presented at the 62^nd Institute of Psychiatric Services, Oct. 14-17, 2010; Boston, MA.

Ginsberg, L. Long-term safety, tolerability, and efficacy of extended-release carbamazepine in a large clinical practice: a chart review study. Poster presented at the 62^nd Institute of Psychiatric Services, Oct. 14-17, 2010; Boston, MA.

Findling, R., Ginsberg, L., Adeyl, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., DeLeon, A., Turgay, A. Parent-Reported Executive Function Behaviors and Clinician Ratings of ADHD Symptoms in Children Treated With Lisdexamphetamine Dimesylate. Poster presented at the 57^th annual meeting of the American Academy of Child and Adolescent Psychiatry, Oct. 26-31, 2010; New York, NY.

Wang, P., Erickson, C., Ginsberg, L., King, B. Improvements in Social and Communicative Function Associated with STX209 (Arbaclofen) Treatment: Results of an 8-week, Open-Label Medication Trial in ASD. Poster presented at Autism 2010 Geneva Center for Autism International Symposium, Nov. 3-5, 2010; Toronto, ON.

Findling, R., Adeyl, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., DeLeon, A., Ginsberg, L. Parent-Reported Executive Function Behaviors and Clinician Ratings of ADHD Symptoms in Children Treated With Lisdexamphetamine Dimesylate. Poster presented at the 23rd annual meeting of the United States Psychiatric and Mental Health Congress, Nov. 18-21, 2010; Orlando, FL.

Turgay, A., Ginsberg, L., Sarkis, E., Jain, R., Adeyi, B., Gao, J., Dirks, B., Babcock, T., Scheckner, B., Richards, C., Lasser, R., Findling, R. Executive Function Deficits in Children with Attention -Deficit/Hyperactivity Disorder and Improvement with Lisdexamfetamine Dimesylate in an Open-Label Study, Journal of Child and Adolescent Psychopharmacology 2010; 20 (6): 503-511.

Ginsberg, L., Oubre, A., Daoud, Y. L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode, Innovations in Clinical Neuroscience 2011; 8(1):19-28

Ginsberg, L., Katic, A., Adeyi, B., Dirks, B., Babcock, T., Lasser, R., Scheckner, B., Adler, L. Long-term Treatment Outcomes with Lisdexamfetamine Dimesylte for Adults with Attention-Deficit/Hyperactivity Disorder Stratified by Baseline Severity, Current Medical Research & Opinion 2011; 27(6):1097-1107.

Wang, P., Erickson, C., Ginsberg, L., Rathmell, B., Cherubini, M., Zarevics, P., King, B. Effects of STX209 (arbaclofen) on Social and Communicative Function in ASD: Results of An 8-Week Open Label Trial. Oral Session presented at the 10th International Meeting for Autism Research (IMFAR), May 12-14, 2011; San Diego, CA.

Veenstra-VanderWeele, J., King, B., Erickson, C., Ginsberg, L., Melmed, R., Scahill, L., Sikich, L., McCracken, J., Rathmell, B., Carpenter, R., Bear, M., Wang, P. An Open Label Trial of Arbaclofen in Autism Spectrum Disorder Shows Improvements in Multiple Symptom Domains. Poster presented at 51^st annual meeting of the New Clinical Drug Evaluation Unit, June 13-16, 2011; Boca Raton, FL.

Erickson, C., Ginsberg, L., Wang, P. Rathmell, B., King, B. Results of an 8-Week, Open-label Trial of STX209 (Arbaclofen) in Autism Spectrum Disorders: Social and Communication Function. Poster presented at the Society of Developmental and Behavioral Pediatrics, Sept. 16-19, 2011; San Antonio, TX.

Erickson, C., Ginsberg, L., Wang, P. Rathmell, B., King, B. Results of an Open-label Trial of STX209 (Arbaclofen) in Autism Spectrum Disorders: Social and Communication Function. Poster presented at 40th Annual Meeting of the Child Neurology Society, Oct. 26-29, 2011; Savannah, GA.

Erickson, C., Ginsberg, L., Veenstra-VanderWeele, J, Melmed, R., Sikich, L., Scahill, L., McCracken, J., Rathmell, B., Carpenter, R., Wang, P., Bear, M., King, B. Effects of STX209 (Arbaclofen) on Social and Communication Function in Autism Spectrum Disorders: Results of an 8-Week Open-Label Trial. Poster presented at the 58^th annual meeting of the American Academy of Child and Adolescent Psychiatry, Oct. 18-23, 2011; Toronto, ON.

Weisler, R., Ginsberg, L., Dirks, B., Deas, P., Adeyi, B., Adler, L. Efficacy of Lisdexamfetamine Dimesylate on Self- and Informant-Reported Executive Dysfunction in Adults with Attention-Deficit/Hyperactivity Disorder. Poster presented at the 165^th annual meeting of the American Psychiatric Association, May 5-9, 2012; Philadelphia, PA.

Findling, R., Ginsberg, L. A Phase IV, Multi-Center, Open-Label Study of Extended-Release Carbamazepine in the Treatment of Manic or Mixed States in Youths Aged 10-17 Years. Poster presented at the 165^th annual meeting of the American Psychiatric Association, May 5-9, 2012; Philadelphia, PA.

Katic, A., Ginsberg, L., Jain, R., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Richards, C., Lasser, R., Turgay, A., Findling, R. Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate, Journal of Attention Disorders 2012; 16 (5): 384-97. E Pub Dec. 20, 2010.

Findling, R., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., DeLeon, A., Ginsberg, L. Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention -Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate, Journal of Child and Adolescent Psychopharmacology 2013; 23 (1): 28-35.

Ginsberg, L., Wetstein, T., A Natural, Novel Approach in the Treatment of Depression: Advanced Generation Folate Therapy Completely Addresses the Needs of the Remethylation and Transsulfuration Cycles. Poster presented at the 2013 NEI Psychopharmacology Congress, Nov. 14-17, 2013; Colorado Springs, CO.

Weisler, R., Ginsberg, L., Dirks, B., Deas, P., Adeyi, B., Adler, L. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study, Journal of Attention Disorders 2017: 21 (14): 1198-1207. E Pub Jan. 24, 2014.

Erickson, C.A., Veenstra-Vanderweele, J.M., Melmed, R.D., McCracken, J.T., Ginsberg, L.D., Sikich, L., Scahill, L., Cherubini, M., Zarevics, P., Walton-Bowen, K., Carpenter, R.L., Bear, M.F., Wang, P.P., King, B.H. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study. J Autism Dev Disorders 2014; 44 (4): 958-64.

Findling, R., Ginsberg, L. The Safety and Effectiveness of Open-label Extended-Release Carbamazepine in the Treatment of Children and Adolescents with Bipolar I Disorder Suffering from a Manic or Mixed Episode. Neuropsychiatric Disease and Treatment 2014; 10: 1589-1597.

Herscu, P., Handen, B., Arnold, L., Snape, M., Bregman, J., Ginsberg, L., Hendren, R., Kolevzon, A., Melmed, R., Mintz, M., Minshew, N., Sikich, L., Attalla, A., King, B., Owley, T., Childress, A., Chugani, H., Frazier, J., Cartwright, C., Murphy, M., The Autism Speaks Autism Clinical Trials Network. The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autism Disorder. Journal of Autism and Developmental Disorders 2020 Sep;50(9):3233-3244. 2019 July 2 E pub ahead of print.